Abstract
Background and Objective
Despite its prevalence and impact, breakthrough pain (BTP) in chronic non-cancer pain with neuropathic component, has not been well studied and is sometimes unrecognized and often undertreated. We evaluated the efficacy of sublingual fentanyl tablet (SLF) for the treatment of BTP in opioid-tolerant patients with chronic musculoskeletal pain with neuropathic component in terms of relief of pain intensity and assessed whether hypothetical pain relief impacts on quality of life (QoL).
Methods
A multicenter, prospective, open-label study was conducted over a 30-day period. Efficacy was evaluated using a visual analogue scale (VAS) and time to onset of action of SLF. The incidence of dependence was assessed by the Leeds Dependence Questionnaire (LDQ). Changes in QoL were evaluated using the Brief Pain Questionnaire (BPI) and the EuroQol (EQ-5D). Adverse events (AE) were recorded throughout.
Results
106 patients were enrolled and 105 completed the study. The average pain reduction across the study was −3.30 points [95 % confidence interval (CI) 2.9–3.7; P < 0.0001]. Pain intensity improvement from baseline was statistically significant at first assessment and all subsequent assessments (P < 0.0001). The most common AEs included nausea (33.87 %), constipation (33.06 %), somnolence (19.35 %) and vomiting (6.45 %). No significant differences were observed on LDQ (P = 0.71). QoL as measured by BPI showed statistically significant improvement in all four severity items and all interference items (P < 0.0001) and a significant improvement in the percentage of pain relief reported by patients (P < 0.0001). EQ-5D results showed a trend towards improvement. Mean self-rate health status, as measured by the EQ VAS scale increased significantly (P < 0.0001).
Conclusion
SLF provides significant reductions in BTP intensity. The results of the BPI and EQ-5D assessments indicate that pain relief is associated with improvement of functioning and enhancement of QoL.
Similar content being viewed by others
References
Treede RD, Jensen TS, Campbell JN, et al. Redefinition of neuropathic pain and a grading system for clinical use: consensus statement on clinical and research diagnostic criteria. Neurology. 2008;70:1630–5.
Argoff CE. The coexistence of neuropathic pain, sleep and psychiatric disorder: a novel treatment approach. Clin J Pain. 2007;23:15–22.
McCarberg BH, Billington R. Consequences of neuropathic pain: quality of life issues and associated costs. Am J Managed Care. 2006;12:S263–8.
Foley KM. Opioids and chronic neuropathic pain. N Engl J Med. 2003;348:1279–81.
Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–30.
Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review on efficacy and safety. Pain. 2004;112:372–80.
Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273–81.
Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain. 2006;7:583–91.
Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev. 2013;10:CD004311.
Simpson DV, Messina J, Xie F, et al. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain. A multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:588–601.
Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9–19.
Moore RA, Derry S, Wiffen PJ. Challenges in design and interpretation of chronic pain trials. Br J Anaesth. 2013;111:38–45.
European Medicines Agency. Guideline for good clinical practice: ICH Topic E6 (R1). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf. Accessed 7 May 2014.
Abstral (Sublingual Fentanyl Citrate). Summary of product characteristics. Available at: http://www.abstral.co.uk/downloads/Abstral_SPC.pdf. Accessed 7 May 2014.
Perez C, Galvez R, Huelbes S, et al. Validity and reliability of the Spanish version of the DN4 (Douleur neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes. 2007;5:66.
EuroQol Group. EuroQol a new facility for the measurement of health related quality of life. Health Policy. 1990;16:199–208.
Badia X, Muriel C, Gracia A, et al. Validation of Brief Pain Inventory in patients with oncological pain [in Spanish]. Med Clin (Barc). 2003;120:52–9.
Raistrick D, Bradshaw J, Tober G, et al. Development of the Leeds Dependence Questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction. 1994;89:563–72.
Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse and Mental Health Administration; 1976. p. 217–22. (313–31).
Katz WA, Barkin RL. Dilemmas in chronic/persistent pain management. Am J Ther. 2008;15:256–64.
Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain. 2004;109:514–9.
Chaparro LE, Furlan AD, Deshpande A, et al. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev. 2013;8:CD004959.
McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;8:CD006146.
Lennernas B, Frank-Lissbrant I, Lennernas H, et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliat Med. 2010;24:286–93.
Chou R, Ballantyne JC, Fanciullo GJ, et al. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10:147–59.
Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877–85.
Nalamachu S, Hassman D, Wallace MS, et al. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin. 2011;27:519–30.
Guitart J, Vargas I, De Sanctis V, et al. Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study. Clin Drug Invest. 2013;33:675–83.
Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically important difference in pain outcome measures. Pain. 2000;88:287–94.
Webster LR, Messina J, Xie F, et al. Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain. J Opioid Manag. 2011;7:297–308.
Überall MA, Muller-Schwefe GH. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin. 2011;27:1385–94.
Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develops abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9:444–59.
Passik SD, Messina J, Golsorkhi A, et al. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. J Pain Symptom Manag. 2011;41:116–25.
Acknowledgments
The authors thank María José Sánchez for editing the manuscript and editorial assistance. Authors declare that there are no known conflicts of interest associated with this publication and there are no conflicts of interest that could inappropriately influence this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cánovas-Martínez, L., Carceller-Ruiz, J.J., Díaz-Parada, P. et al. Efficacy and Safety of Sublingual Fentanyl Tablets for the Management of Breakthrough Pain in Patients with Chronic Musculoskeletal Pain with Neuropathic Component: Multicenter Prospective Study. Clin Drug Investig 35, 169–177 (2015). https://doi.org/10.1007/s40261-015-0268-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-015-0268-8